Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + docetaxel for biomarker-selected relapsed/refractory metastatic colorectal cancer
NL-OMON44946Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by Vrije University Medical Center. Primary endpoint: Objective response rate. Started May 2015; status: active, not recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON44946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44946.